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Although genetically engineered mouse (GEM)
models are often used to evaluate cancer therapies,
extrapolation of such preclinical data to human can-
cer can be challenging. Here, we introduce an
approach that uses drug perturbation data from
GEM models to predict drug efficacy in human can-
cer. Network-based analysis of expression profiles
from in vivo treatment of GEM models identified
drugs and drug combinations that inhibit the activity
of FOXM1 and CENPF, which are master regulators
of prostate cancer malignancy. Validation of mouse
and human prostate cancer models confirmed the
specificity and synergy of a predicted drug combina-
tion to abrogate FOXM1/CENPF activity and inhibit
tumorigenicity. Network-based analysis of treatment
signatures from GEM models identified treatment-
responsive genes in human prostate cancer that
are potential biomarkers of patient response. More
generally, this approach allows systematic identifica-
tion of drugs that inhibit tumor dependencies,
thereby improving the utility of GEMmodels for prior-
itizing drugs for clinical evaluation.
INTRODUCTION
Recent large-scale genomic analyses have led to the identifica-
tion of ‘‘actionable’’ driver genes of specific cancers that are
therapeutically accessible, including oncogene and non-onco-
gene dependencies (Al-Lazikani et al., 2012; Garraway and
Lander, 2013; Luo et al., 2009; Rubio-Perez et al., 2015). How-
ever, the accurate and efficient identification of drugs and drug
combinations that inhibit such drivers within specific tumor con-
texts represents a major challenge, particularly for transcrip-2060 Cell Reports 12, 2060–2071, September 29, 2015 ª2015 The Ational regulators that, in general, are pharmacologically inacces-
sible. Genetically engineered mouse (GEM) models are well
suited to empower investigations of targeted inhibitors in the
context of the native tumor microenvironment in vivo (Abate-
Shen and Pandolfi, 2013; Politi and Pao, 2011; Sharpless and
Depinho, 2006). However, species differences with respect to tu-
mor histology, physiology, pharmacology, andmetabolism often
preclude direct extrapolation of preclinical findings from mouse
models to human cancer.
In the current study, we introduce an innovative regulatory-
network-based method that uses expression profiles from
drug-treated GEM models to predict drugs and drug combina-
tions that specifically inhibit the activity of established human
cancer dependencies. We focus this proof-of-concept study
on prostate cancer, a disease characterized by heterogeneity
of its causal mechanisms and range of disease outcomes
(Chang et al., 2014; Cooperberg et al., 2005; Roychowdhury
and Chinnaiyan, 2013; Shen and Abate-Shen, 2010). In partic-
ular, while most locally invasive prostate tumors are curable,
recurrent or aggressive tumors initially respond to androgen
deprivation therapy but ultimately relapse to castration-resistant
metastatic disease, which is nearly always fatal (Ryan and Tin-
dall, 2011; Scher and Sawyers, 2005). While treatment options
for castration-resistant metastatic prostate cancer have signifi-
cantly improved in recent years (Mukherji et al., 2014; Rathkopf
and Scher, 2013; Wong et al., 2014), none of the available treat-
ments are as yet curative.
We have recently generated genome-wide reverse-engi-
neered regulatory networks (henceforth ‘‘interactomes’’) for
both mouse and human prostate cancer (Aytes et al., 2014).
Interrogation of these interactomes identified FOXM1 and
CENPF as master regulators (i.e., key driver genes), which func-
tion synergistically to elicit synthetic lethality and are robust pre-
dictors of poor patient outcome (Aytes et al., 2014). Here, we
show that interrogation of in vivo drug perturbation signatures
from GEM models represents an effective strategy for system-
atic identification of specific drugs and drug combinations thatuthors
Figure 1. Computational Prediction of Drugs that Inhibit FOXM1/CENPF Activity In Vivo
(A) Shown is the strategy for prediction of single drugs. Drug reversion scores were calculated based on the degree to which target genes that are activated (red)
by a master regulator (MR) are inhibited (blue) following drug treatment, and conversely, the degree to which target genes that are repressed (blue) by the MR are
activated (red) following drug treatment (see Supplemental Experimental Procedures).
(B) Heatmap representations of GSEA used to calculate drug reversion scores across a series of GEM models with a series of drugs, as indicated (see Sup-
plemental Experimental Procedures). GSEA were done using the mouse in vivo drug perturbation signatures as the reference and human or mouse FOXM1/
CENPF target genes inferred from their respective prostate cancer interactomes, as indicated, as the query gene set. Global reversion scores (GRSs) were
calculated for each drug by combining the individual NES for each GEM model using a metric based on the Stouffer integration formulation (see Supplemental
Experimental Procedures). Arrows point to the two drugs with the highest GRSs.
(C) Shown is the strategy for prediction of drug synergy. Pairwise combinations of data from individual drug treatments (as in A) were assessed to predict
drugs that effectively revert FOXM1/CENPF target genes when used in combination. Scenario 1 illustrates two drugs that inhibit (i.e., revert) many target
(legend continued on next page)
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inhibit the transcriptional activity of FOXM1/CENPF. Strikingly,
drug combinations that revert transcriptional activity of these
proteins are highly effective in abrogating tumorigenesis in vivo
and well correlated with patient outcome. We propose that this
computational method can be generalized for more effective uti-
lization of preclinical data from GEM models to predict optimal
drugs and drug combinations and thereby dramatically improve
the utilization of GEMmodels to prioritize compounds for clinical
investigation.
RESULTS
Systematic Inference of FOXM1/CENPF Inhibitors
In Vivo
The current methodology is predicated on our previous analyses
showing that expression of the target genes of a given master
regulator (MR) (its regulon) represents an effective reporter to
predict the activity of theMR for a given cancer phenotype (Aytes
et al., 2014; Carro et al., 2010; Chen et al., 2014). Here, we have
extended this concept to evaluate whether such regulon can be
used as a reporter to quantitatively measure the ability of a drug
or drug combination to inhibit the activity of the corresponding
MR. In general, reversion of MR activity would correspond to
the ability of a given drug to downregulate its activated target
genes and upregulate its repressed targets (Figure 1A). As a
proof of concept for this approach, we evaluated drugs for their
ability to inhibit the master regulator pair, FOXM1/CENPF, which
we have previously established to be a key synthetic lethal de-
pendency of prostate tumor malignancy (Aytes et al., 2014). In
particular, we tested whether candidate therapeutic agents
could be prioritized based on in vivo perturbation by assessing
their ability to ‘‘reverse’’ the FOXM1/CENPF regulon. We
focused on the activated shared targets of FOXM1/CENPF,
since the number of repressed targets is too few for analysis.
However, both activated and repressed targets may be used in
general.
To assess this strategy, we used a drug perturbation dataset
that includes drugs with known prostate cancer relevance,
such as those that inhibit the androgen receptor, or key signaling
pathways such as phosphatidylinositol 3-kinase (PI3K)/mTOR or
MAP kinase or standard chemotherapy (Aytes et al., 2014; see
Supplemental Experimental Procedures). In vivo drug perturba-
tion studies were performed using multiple GEM models repre-
sentative of advanced prostate cancer (Aytes et al., 2014; see
Supplemental Experimental Procedures) to avoid potential bias
introduced by any individual model. The in vivo drug perturbation
data were analyzed by gene set enrichment analysis (GSEA)
(Subramanian et al., 2005) to assess the inhibition (i.e., reversion)
of FOXM1/CENPF shared target genes; analyses were per-genes, thereby resulting in strong reversion. Scenario 2 illustrates two other drug
reversion.
(D) Heatmap representation depicting global synergistic reversion scores (GSRS
FOXM1/CENPF human target genes. GSRSs were calculated by combining the s
Supplemental Experimental Procedures). Heatmap intensity (blue) represents th
highest combined GSRS.
(E) Heatmap showing the relative expression levels of FOXM1/CENPF target ge
shown are genes that are not reverted (i.e., non-responsive) to these drugs.
Figure S1 is related to Figure 1; computational predictions of GRSs and GSRSs
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Using GSEA, we obtained a normalized enrichment score (NES)
for each drug signature and each GEM model, which we define
as the reversion score (RSFOXM1/CENPF), to assess the com-
pound’s ability to inhibit FOXM1/CENPF activity in a specific
GEM model (Table S1). From these analyses, a global reversion
score (GRSFOXM1/CENPF) was assigned for each drug by inte-
grating each of the GEM-specific RSFOXM1/CENPF scores, using
a metric based on Stouffer’s integration formulation (Whitlock,
2005) (Figure 1B; Figure S1; Supplemental Experimental Proce-
dures). Thus, drugs that most effectively inhibit FOXM1/CENPF
activity are those having the most negative GRSFOXM1/CENPF.
Notably, FOXM1/CENPF target genes from either mouse or hu-
man yielded equivalent GRSFOXM1/CENPF (Figure 1B; Table S1),
indicating conservation of the predicted drug response between
mouse and human prostate cancer.
Among the individual drugs tested in the GEMmodels, the two
with the most significant negative GRSFOXM1/CENPF were rapa-
mycin and PD0325901. These drugs inhibit the PI3K/mTOR
and MAP kinase signaling pathways, respectively, which are
frequently dysregulated in advanced prostate cancer (Aytes
et al., 2013; Kinkade et al., 2008; Taylor et al., 2010). Specifically,
the GRSs for rapamycin wereGRSH =13.9 (human targets) and
GRSM =16.9 (mouse targets) and for PD0325901 were GRSH =
8.1 andGRSM =9.9 (Figure 1B; Table S1). In contrast to rapa-
mycin and PD0325901, other drugs including docetaxel, a stan-
dard-of-care chemotherapy for advanced prostate cancer
(Pienta and Smith, 2005), were not predicted to be effective for
inhibiting the FOXM1/CENPF regulon (GRSH = 5.8 and GRSM =
5.6; Figure 1B; Figure S1).
Systematic Inference of Drug Synergy
Next, we tested whether this computational approach could be
extended to infer drug combinations that cooperate to inhibit
MR activity, again using FOXM1 and CENPF as a proof of
concept. These analyses are based on the hypothesis that effec-
tive drug combinations should induce a more significant reversal
of MR-specific regulon expression, compared to the individual
drugs (Figure 1C; Supplemental Experimental Procedures).
Notably, such logic can be implemented based on individual
drug signatures, without requiring in vivo signatures from drug
combinations, which vastly increases the experimental effi-
ciency for prioritizing drug combinations based on in vivo pre-
clinical data.
To estimate a global synergistic reversion score (GSRS) for
each drug pair, we assessed the predicted reversion score for
all possible combinations of two drug treatments across each
of the GEM models. First, the synergistic reversion score (SRS)
was calculated for each GEM model as an harmonic means that inhibit (i.e., revert) relatively few target genes, thereby resulting in weak
s) for each possible pair of drugs across the series of GEM models based on
ynergistic reversion scores for targets affected by the drug combinations (see
e predicted degree of reversion (GSRS); arrows indicate drug pairs with the
nes reverted by treatment with rapamycin or PD0325901 versus vehicle; also
are provided in Tables S1 and S2, respectively.
uthors
Figure 2. Validation of Drug Efficacy, Synergy, and Specificity in Prostate Cancer Cells
(A) Real-time PCR of mRNA expression levels of FOXM1 and CENPF and their shared target genes following treatment with rapamycin and/or PD0325901 or
docetaxel in DU145 human prostate cancer cells (top) or NPK mouse prostate tumors (bottom).
(B and C) Colony formation assays in the indicated human prostate cancer cells, PC3, DU145, 22Rv1, and LNCaP, following treatment with rapamycin (Rap) and/
or PD0325901 (PD), or docetaxel (Doc). (B) Representative colony formation assays. (C) Quantification of independent assays performed in triplicate.
(legend continued on next page)
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(F-score) that first maximizes the number of unique targets
affected by each drug, and then the total number of targets
affected by both drugs (Figure 1C; Supplemental Experimental
Procedures). These analyses identified several combinations,
most of which included rapamycin or PD0325901, which were
predicted to be more effective than the individual compounds
based on their GSRSs (Figure 1D; Table S2). In particular, the ra-
pamycin + PD0325901 combination was predicted to have the
strongest global inhibition of the FOXM1/CENPF regulon, both
with respect to total number of targets affected by both drugs
and the number of unique targets affected by each drug, result-
ing in the most significant negative global synergistic reversion
score (GSRSH = 40.4; p value < 0.001 compared to a random
model; see Supplemental Experimental Procedures). This theo-
retical prediction was validated by assessment of FOXM1/
CENPF target genes that were reverted by rapamycin or
PD0325901 following drug treatment in vivo (Figure 1E).
Experimental Validation of Drug Specificity and Synergy
in Cell Culture
Based on these computational predictions, we performed exper-
imental validation to assess whether rapamycin and/or
PD0325901 specifically inhibit the FOXM1/CENPF regulon in
relevant mouse and human prostate cancer cell culture models,
and if so, whether these drugs affect cell growth and tumorige-
nicity in a FOXM1/CENPF-dependent manner. First, we vali-
dated the underlying computational prediction that treatment
with rapamycin and PD0325901 reverts the expression of shared
target genes of FOXM1/CENPF. Using real-time PCR, we found
that treatment with rapamycin and PD0325901, but not doce-
taxel, inhibited expression of both FOXM1 and CENPF as well
as their shared target genes in several human and mouse pros-
tate cancer models (Figure 2A; Figure S2A). This inhibition of
target genes was coincident with inhibition of the corresponding
signaling pathways, namely PI3K/mTOR and MAP kinase in the
mouse and human cells (Figures S2B and S2C). Notably, inhibi-
tion of colony formation was significantly greater when the
drugs were combined than when used individually (Figure 2B,
C), which supports the computational prediction of rapamycin +
PD0325901 synergy.
To address the specificity of the rapamycin + PD0325901 drug
combination for inhibition of FOXM1/CENPF activity, we as-
sessed whether this combination was preferentially more potent
in contexts having high levels of FOXM1/CENPF activity. First,
we surveyed the expression and activity of FOXM1/CENPF in a
series of human and mouse cell lines; ‘‘activity’’ was determined
experimentally by analyses of the expression of FOXM1/CENPF
shared target genes (Figure 2D; Figures S2D–S2F). These
studies revealed that PC3 cells have the highest levels of
FOXM1/CENPF activity, whereas LNCaP cells have lower levels
(Figure 2D). Correspondingly, human prostate cancer cells with
higher levels of FOXM1/CENPF activity had greater response(D) (Left) Relative activity of FOXM1/CENPF in human prostate cancer cells lines. A
target genes (see Figure S2F). (Right) Relative drug response assessed for FO
treatment with rapamycin + PD0325901 (Rap + PD) or docetaxel (Doc). Differen
indicated, p values are represented as *p < 0.01, **p < 0.001, and ***p < 0.0001.
Figures S2 and S3 are related to Figure 2.
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inhibition of activity and colony formation, whereas LNCaP cells,
which have low levels of FOXM1/CENPF activity, had a modest
response to rapamycin + PD0325901 (Figures 2B–2D). In
contrast, this relationship to FOXM1/CENPF activity was not
observed following docetaxel treatment of these cells (Figures
2B–2D). Similar findings were observed in mouse prostate can-
cer cells wherein response to rapamycin + PD0325901 treatment
was correlated with the relative levels of FoxM1/Cenpf activity
(Figures S2D and S2E).
Moreover, the dependence on FOXM1/CENPF in the human
prostate cancer cells was evident by the reduction in the
half maximal inhibitory concentration (IC50) for rapamycin +
PD0325901, but not docetaxel, following the silencing of both
FOXM1 and CENPF in human prostate cancer cell lines with
high levels of activity (Figure S3). Conversely, overexpression of
FOXM1 and CENPF in a non-prostate cancer cell line, HEK293,
resulted in an increase in the IC50 for rapamycin + PD0325901,
but not docetaxel (Figure S3). Taken together, these findings vali-
date the computational prediction that FOXM1/CENPF activity is
specifically inhibited by rapamycin + PD0325901.
Experimental Validation of Drug Efficacy and Specificity
In Vivo
The synergistic effects of combined treatment with rapamycin +
PD0325901 were even more dramatic in vivo. In particular, we
performed preclinical studies using NPK mice (Nkx3.1CreERt2;
Ptenflox/flox; KrasLSL-G12D/+), which model aggressive, metastatic
prostate cancer that is dependent on FOXM1/CENPF activity
(Aytes et al., 2013, 2014). Tumor-bearing NPKmice were treated
with rapamycin and/or PD0325901, or docetaxel, for 5 days (i.e.,
the dynamic response cohort) or 1 month (i.e., the therapeutic
response cohort) (Figure 3A; Table S3). Mice were then either
sacrificed for analysis or monitored for the effects of drug treat-
ment on survival and metastasis (i.e., the survival response
cohort) (Figure 3A; Table S3).
Whereas treatment with either drug individually had a modest
therapeutic benefit at the various endpoints, the combination of
rapamycin + PD0325901 had a profound effect at all tumor end-
points in the therapeutic response cohort (Figures 3B–3E). In
particular, treatment with rapamycin + PD0325901, but not do-
cetaxel, resulted in profound abrogation of the histological
phenotype, coincident with inhibition of relevant signaling path-
ways, as evident by immunohistochemistry (Figure 3B). More-
over, tumors treated with rapamycin + PD0325901, but not do-
cetaxel, displayed a significant decrease in cellular proliferation
(p < 0.0001) (Figure 3C), as well as significant reduction in tumor
burden, as measured by tumor weight (p = 0.003) and tumor vol-
ume using MRI (p < 0.01) (Figures 3D and 3E). Furthermore,
these effects on phenotype and tumor burden were accompa-
nied by a significant improvement in survival (p < 0.0001) (Fig-
ure 3F), as well as a 3-fold reduction in the incidence ofctivity levels were calculated based on expression levels of 10 FOXM1/CENPF
XM1/CENPF activity levels in the human prostate cancer cell lines following
ces between treatment groups were assessed using Student’s t test. When
Bars represent mean ± SD.
uthors
Figure 3. Validation of Drug Synergy and Specificity In Vivo
(A) Shown is the design of preclinical studies. NPKmice were induced to form tumors by delivery of tamoxifen at 2 months of age as in (Aytes et al., 2013). Mice
were treated with rapamycin and/or PD032590, or docetaxel for 5 days (dynamic response cohort) or 1 month, following which mice were sacrificed for analyses
(therapeutic response cohort) or monitored for survival (survival response cohort).
(B–E) Analysis of the therapeutic response cohort following treatment with rapamycin (Rap) and/or PD0325901 (PD) or docetaxel (Doc) as indicated (n = 5 mice/
treatment group). (B) Representative sections of H&E staining or immunohistochemical staining for the indicated markers of the PI3K/mTOR or MAP kinase
signaling pathways; scale bars represent 100 mm. (C) Relative cellular proliferation following drug treatment as determined by the percent of Ki67-positive cells
relative to total epithelial cells. (D) Prostate weight (in grams) following drug treatment. (E) Longitudinal MRI imaging showing representative images following drug
treatment with tumor volumes indicated. The panel to the right represents the net change in tumor volume following 1 month of drug treatment.
(F–H) Shown is analysis of the survival response cohort. (F) Survival analysis showing the improvement in survival following treatment with rapamycin and
PD0325901 (Rap + PD) compared with the vehicle-treated mice. (G) Percentage of mice with disseminated cells in the bone marrow and (H) percentage of mice
with lung metastases following treatment with vehicle (Veh) or rapamycin + PD0325901 (Rap + PD) (n = 10 mice/treatment group). Differences between groups
were assessed using Student’s t test; bars represent mean ± SD. In (F), p value corresponds to a log-rank test.disseminated tumor cells in the bonemarrow and a 4-fold reduc-
tion in the incidence of lung metastases (Figures 3G and 3H).
Together, these findings validate the concept that treatment
with rapamycin + PD0325901 inhibits growth of FOXM1/
CENPF-dependent tumors.
Relationship of Mouse Drug-Treatment Signatures to
Human Cancer
Given the striking reduction in tumor and metastatic burden
following treatment with rapamycin + PD0325901, we evaluatedCell Repwhether this combination might be sufficient to broadly inhibit
molecular processes associated with advanced, FOXM1/
CENPF-dependent prostate cancer. We addressed this ques-
tion by analyzing signatures obtained by differential gene
expression analysis of NPK prostate tumors treated with vehicle
or rapamycin + PD0325901 for 1 month (i.e., the therapeutic
response cohort; Table S3), which resulted in extensive abroga-
tion of the tumor phenotype (see Figure 3). We compared this
‘‘therapeutic response’’ signature to a reference mouse ‘‘tumor’’
signature, corresponding to differential gene expressionorts 12, 2060–2071, September 29, 2015 ª2015 The Authors 2065
between phenotypically wild-type prostates and NPK prostate
tumors, which captures the transition from normal prostate to
fully malignant prostate cancer (Table S3). Strikingly, genes
that were differentially expressed in the therapeutic response
signature were strongly negatively enriched in the mouse tumor
signature (NES = 8.58; p < 0.001) (Figure S4A). Further evi-
dence that rapamycin + PD0325901 treatment results in broad
inhibition beyond their respective target signaling pathways
was provided by biological pathway analysis. In particular, path-
ways that were significantly inhibited (i.e., reverted) following
treatment of the NPK tumors with rapamycin + PD0325901,
but not docetaxel, include several that are important for tumor
progression and are not directly related to mTOR/PI3K/MAP ki-
nase signaling (Figure 4A; Table S4).
To evaluate molecular processes that are inhibited immedi-
ately following drug treatment, we analyzed a ‘‘dynamic
response’’ signature, representing a time point wherein the
drugs are active but the tumor phenotype has not yet been abro-
gated (Figure 3A; Table S3; and data not shown). In particular,
this short-term treatment with rapamycin + PD0325901 resulted
in reversion of FOXM1/CENPF targets, as predicted by our
computational approach (Figure S4B; see Figure 1E). Compari-
son of this ‘‘dynamic response’’ signature to a reference mouse
‘‘malignancy signature,’’ based on comparison of non-malignant
prostate tumors from NP mice to fully malignant NPK tumors
(Aytes et al., 2013), revealed a striking negative enrichment
(i.e., strong reversion) (NES = 8.34; p < 0.001) (Figure 4B), sug-
gesting that the rapamycin + PD0325901 combination inhibits
molecular processes associated with NPK tumor malignancy
even prior to their overt effects on the tumor phenotype.
To assess conservation of these molecular changes with
human prostate cancer, we performed GSEA to compare a hu-
manized version of the mouse dynamic response signature
with human prostate cancer signatures (see Supplemental
Experimental Procedures). We used three independent human
prostate cancer signatures, each of which is based on distinct
clinical endpoints (Table S3): (1) a malignancy signature based
on the Taylor dataset (Taylor et al., 2010), which compares pa-
tients having low Gleason score and no biochemical recurrence
(n = 39) to those with high Gleason score and a short time to
biochemical recurrence (n = 10) (Aytes et al., 2013); (2) a metas-
tasis signature based on the Balk dataset (Stanbrough et al.,
2006), which compares hormone-naive prostate tumors (n =
22) to bone metastases from castration-resistant prostate can-
cer (n = 29) (Aytes et al., 2014); and (3) a survival signature based
on the Sboner dataset (Sboner et al., 2010), which compares
transurethral resections from patients who survived for nearly
200 months (n = 12) to those who died of prostate cancer within
12 months (n = 6) (Wang et al., 2013). Strikingly, the mouse dy-
namic response signature was strongly negatively enriched
when compared with each of these human signatures, indicating
that genes that are consistently overexpressed in aggressive
prostate cancer are inhibited following drug treatment (Taylor
signature NES = 5.48, p < 0.001; Balk signature NES =
5.26, p < 0.001; and Sboner signature NES = 6.40, p <
0.001) (Figure 4C). In contrast, the docetaxel treatment response
signature was eitherminimally or not negatively enriched in these
human signatures (Figure S4C).2066 Cell Reports 12, 2060–2071, September 29, 2015 ª2015 The AWe then asked whether the mouse dynamic response signa-
ture could reverse a ‘‘FOXM1/CENPF activity’’ signature in hu-
man prostate cancer. This FOXM1/CENPF activity signature,
defined using the Sboner dataset (Sboner et al., 2010), corre-
sponds to differential gene expression between patient samples
having low versus high levels of FOXM1/CENPF activity, which
was measured by enrichment of the FOXM1/CENPF regulon in
each patient using single-sample master regulator inference al-
gorithm (ssMARINa) as in Aytes et al. (2014) (see Supplemental
Experimental Procedures). GSEA comparing the ‘‘FOXM1/
CENPF’’ activity signature with the mouse ‘‘dynamic response’’
signature showed strong negative enrichment (NES = 6.43,
p < 0.001) (Figure 4D), which supports the concept that patients
with high levels of FOXM1/CENPF activity should respond more
effectively to rapamycin + PD0325901 treatment. Notably,
similar comparison with a docetaxel treatment response signa-
ture did not indicate such relationship (NES = 0.37, p = 0.77)
(Figure S4D).
We further evaluated the correlation between FOXM1/CENPF
activity levels and predicted treatment response in each patient
in the Sboner dataset estimated using ssMARINa and GSEA,
respectively. We found that inferred FOXM1/CENPF activity
levels and predicted treatment response were strongly corre-
lated (Spearman’s rho = 0.51, p < 2.23 1016) (Figure 4E), which
was not the case for the docetaxel treatment response (Fig-
ure S4E). Taken together, these computational analyses suggest
that the molecular programs (i.e., genes and pathways) specif-
ically inhibited (reverted) by rapamycin + PD0325901 in the
mousemodel are conserved with those that drive aggressive hu-
man prostate cancer, and in particular in patients having high
levels of FOXM1/CENPF activity.
Conservation of Treatment Response in Mouse
and Human Prostate Cancer
Given the conservation in the molecular programs affected by
drug treatment in the GEM models and human prostate cancer,
we next asked whether we could use the mouse treatment
response signature to identify genes predicted to be associated
with treatment response in humans. First, we identified candi-
date rapamycin + PD0325901-responsive genes by interro-
gating the mouse prostate cancer interactome (Aytes et al.,
2014) with the dynamic response signature using the standard
MARINa algorithm to identify MRs of treatment response in the
mouse (Lefebvre et al., 2010). We then compared these MRs
with the orthologous human genes to identify those predicted
both to be regulated by FOXM1/CENPF in human prostate can-
cer and to be downregulated by drug treatment; we refer to these
as ‘‘predicted treatment-responsive genes’’ and distinguish
them from other FOXM1/CENPF target genes that are not pre-
dicted to be responsive to the treatment (Figure 5A). Notably,
real-time PCR analyses confirmed that the expression levels of
these predicted treatment-responsive genes were indeed in-
hibited by rapamycin + PD0325901 in human prostate cancer
cell lines, whereas the expression levels of the predicted
non-responsive genes were not inhibited by such treatment
(Figure 5B).
These treatment-responsive genes (including TOP2A,UHRF1,
ASF1B, MCM4, WHSC1, MCM2, SUV39H1, BLM, BRCA1,uthors
Figure 4. Cross-Species Analyses of Drug-Treatment Response
(A) Heatmap depiction showing representative pathways that are significantly changed following treatment with rapamycin + PD0325901 (Rap + PD) or docetaxel
(Doc) relative to vehicle treatment (Veh). Pathway analysis was done by GSEA using a ‘‘humanized’’ version of the dynamic response allograft tumor signature
(see Table S3 and Supplemental Experimental Procedures). A complete list of pathways is provided in Table S4.
(B–D) GSEA using as the query gene set themouse rapamycin + PD0325901 dynamic treatment response signature (B) or a ‘‘humanized’’ version of this signature
(C and D); normalized enrichment score (NES) and associated p values are shown. In (B), the reference is mouse ‘‘malignancy’’ signature, which represents
differentially expressed genes from NP versus NPKmouse tumors as reported previously (Aytes et al., 2013). In (C), the references are three independent human
tumor signatures (i.e., Taylor, Balk, or Sboner), each of which compare differentially expressed genes representing less aggressive versus more aggressive
prostate cancer specimens (Table S3). In (D), the reference signature represents differentially expressed genes in patients from the Sboner dataset having low
versus high levels of FOXM1/CENPF activity, which was inferred using single sample MARINa (ssMARINa) (see Supplemental Experimental Procedures).
(E) Heatmap showing the correlation in human patients from the Sboner dataset of FOXM1/CENPF activity levels (top) with the corresponding predicted drug-
treatment response for rapamycin + PD0325901 (bottom). As above, FOXM1/CENPF activity was estimated for each patient using ssMARINa. The treatment
response for each patient was inferred using a ‘‘humanized’’ version of the mouse dynamic treatment signature using GSEA (see Supplemental Experimental
Procedures). Correlation coefficient (rho) and associated p value were estimated using Spearman’s correlation.
Figure S4 and Tables S3 and S4 are related to Figure 4.
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Figure 5. Conservation of Treatment Responsive Genes in Human Prostate Cancer
(A) FOXM1/CENPF subnetwork of human target genes predicted to be responsive or non-responsive to treatment with rapamycin + PD0325901 based on
comparison with treatment response for themousemodel. Relative change in activity following drug treatment is indicated by levels of ‘‘blue’’ for genes predicted
to be reverted by the drugs and levels of ‘‘red’’ for those predicted to be activated or unaffected (i.e., non-responsive).
(B) Real-time PCR showing the actual change in expression levels of FOXM1/CENPF target genes following treatment with vehicle or rapamycin + PD0325901.
The ‘‘predicted treatment-responsive genes’’ correspond to those represented by the blue circles in (A), and the ‘‘predicted non-responsive genes’’ to the other
genes. PCR was done using DU145 cells; differences were assessed using t test (p values are represented as *p < 0.01, **p < 0.001, and ***p < 0.0001) and bars
represent mean ± SD.
(C–E) Association of predicted treatment-responsive genes with lethal prostate cancer and disease outcome. (C) Summary table showing the significance of
elevated expression levels in metastases versus primary tumors in the Taylor and Balk datasets (columns on the left; p value was calculated using t test). The
column on the right shows a COX regression model indicating the association based on master regulator activity levels of the predicted treatment-responsive
genes with prostate cancer-specific survival estimated for patients in the Sboner dataset; COX p value was calculated using Wald test (NA, sufficient targets not
represented; NS, not significant). (D) Oncoprint visualization from cBioportal showing the percent of alterations of the predicted treatment-responsive genes in
metastases samples from the Taylor dataset. (E) Heatmap showing the master regulator activity levels of treatment-responsive genes in primary tumors versus
bone metastases from the Balk dataset.
(F) Heatmap comparing themaster regulator activity levels of the treatment-responsive genes (upper rows) across each patient in the Sboner dataset with inferred
treatment response for each patient (Rap +PD, bottom row). The activity levels and the treatment response for each patient were estimated using single-sample
MARINa (ssMARINa) and GSEA, respectively (see Supplemental Experimental Procedures). The correlation between the average activity levels of all treatment-
responsive genes and the predicted response was estimated using Spearman’s correlation.
(G) Kaplan-Meier survival analysis based on the master regulator activity levels of predicted treatment-responsive genes in the Sboner dataset using prostate
cancer-specific survival as the endpoint. The p value was estimated using a log-rank test of the difference in outcome between patients with higher activity levels
(red) and those with lower/no activity (blue).
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CCNA2, E2F1, andMYBL2) have known functions in DNA repair,
epigenetic modifications, cell cycle, proliferation, and/or sur-
vival, which are all associated with cancer malignancy. Notably,
each of these is overexpressed in advanced human prostate
cancer, and their activity levels are associated with disease
outcome, as shown by univariate analyses using a COX propor-
tional hazard model on the Sboner dataset (Figures 5C and 5D).
Moreover, analyses based on the Balk dataset revealed robust
activity levels of the treatment-responsive genes in metastatic
samples compared to primary tumors (Figure 5E).
We further demonstrated the association of the activity levels
of the treatment-responsive genes with drug response on a pa-
tient-by-patient basis, estimated using ssMARINa and GSEA,
respectively, on the Sboner dataset (Figure 5F). In particular,
the average activity levels of treatment-responsive genes were
strikingly correlated with the rapamycin + PD0325901 drug
response (Spearman rho = 0.57, p < 2.2 3 1016) (Figure 5F),
similar to that observed for the FOXM1/CENPF activity (see Fig-
ure 4D). Most notably, multivariate Kaplan-Meier survival anal-
ysis on the Sboner dataset to evaluate disease-specific survival
revealed that patients with higher activity levels of the treatment-
responsive genes have a shorter time to prostate cancer-spe-
cific death compared to patients with lower activity levels
(log-rank p value = 1.7 3 105) (Figure 5G). Importantly, the ac-
tivity of the treatment-responsive subnetwork of the FOXM1/
CENPF regulon was more significant than the FOXM1/CENPF
regulon (log-rank p value = 1.3 3 104) and also outperformed
a random comparable set of genes with respect to the COX pro-
portional hazard model (p value for improvement < 0.001) and
Kaplan-Meier survival analysis (p value for improvement <
0.015) (see Supplemental Experimental Procedures). Taken
together, these findings suggest that computationally predicted
treatment-responsive genes can be used to identify patients that
are likely to benefit from treatment with drugs that co-target the
PI3K/mTOR and MAP kinase signaling pathways and provide a
proof of concept for the overall approach.
DISCUSSION
In this study, we introduce a generalizable computational
approach to extrapolate in vivo preclinical treatment data from
GEMmodels to inform on human cancer treatment. Our method
infers drug efficacy based on the ability of a given drug to revert
the transcriptional regulon of key dependencies that drive the tu-
mor phenotype. Importantly, we show that this method can be
used to prioritize drug combinations based on analysis of individ-
ual compounds, which greatly enhances the value of in vivo pre-
clinical analyses of compounds in mice. We demonstrate this
approach with a proof-of-concept study based on identification
of drugs and drug combinations that inhibit the activity of
FOXM1/CENPF, which were chosen for their established rele-
vance for lethal prostate cancer (Aytes et al., 2014). However,
this approach should be applicable to identify candidate drugs
and drug combinations for many other driver gene(s) of interest
and not limited to prostate cancer. Notably, the molecular pro-
grams affected by drug treatment in the GEM model are well
conserved with human prostate cancer, which supports the
concept that analyses of drug-treatment data from mouseCell Repmodels can be used to identify treatment-responsive genes for
human prostate cancer. Thus, we have described a method to
identify drugs and drug combinations that specifically inhibit
cancer driver genes, as well as to identify potential biomarkers
to predict the efficacy of drug treatments for individual patients.
Several features of our approach distinguish it from other stra-
tegies previously used to screen for drug response in human
cancer. First, most other approaches have been based on ana-
lyses of cancer cell lines in culture (e.g., Barretina et al., 2012;
Garnett et al., 2012), whereas our study is based on drug pertur-
bation of GEMmodels in vivo. Thus, we evaluate drug efficacy in
the context of the native tumor microenvironment and intact im-
mune system, which are now widely recognized as being essen-
tial for drug response in vivo, particularly given recent advances
in immunotherapy. Although the tumor context of any individual
GEMmodel is unlikely to fully recapitulate that of human cancer,
we address this limitation by analyzing multiple distinct GEM
models to avoid idiosyncratic GEM-specific biology. Indeed,
we have observed a remarkable concordance of the molecular
consequences of drug treatment between our ‘‘consensus’’ an-
alyses of mouse models and human prostate cancer.
A second distinguishing feature of our approach is its ability to
identify synergistic drug combinations based on single-agent
treatment data. From a practical standpoint, the number of drugs
that can be feasibly evaluated using in vivo perturbations in a se-
ries of GEM models is limited. Therefore, the ability to evaluate
the efficacy of drug combinations by profiling a relatively small
number of single drugs (e.g., the 100 most relevant compounds)
would allow assessment of a very large potential combination
therapy space (e.g., 4,950 combinations), thus affording signifi-
cant economy of scale.
A third important feature is that our computational method
identifies drugs based on their ability to inhibit specific drivers
of the tumor phenotype, rather than on overall toxicity or inhibi-
tion of more general tumor-related parameters. In particular,
the method evaluates the efficacy of drug response based on in-
hibition of the transcriptional regulon of specific master regula-
tors of interest. Furthermore, our computational analysis of treat-
ment response in the GEM models in vivo has also identified
treatment-responsive genes that are conserved in human pros-
tate cancer. We propose that such treatment-responsive genes
may serve as surrogate biomarkers to infer the potential efficacy
of drug treatments in patients. In particular, our current findings
suggest that previous analyses may have underestimated the
value of molecular inference of preclinical data from GEM
models for not only predicting optimal drug combinations but
also identifying molecular markers for predicting treatment
response to such drugs.
The PI3K/mTOR and MAP kinase signaling pathways are
known to be dysregulated in many advanced prostate cancers
(Aytes et al., 2013; Kinkade et al., 2008; Taylor et al., 2010).
Currently, drugs that target these pathways (albeit not rapamycin
and PD0325901) are being evaluated in numerous clinical trials
for prostate cancer and many other solid tumors, including com-
bination-therapy regimes. Results from the current study as well
as previous work (Aytes et al., 2014) suggest that aberrant levels
of FOXM1 and CENPF, as assessed by immunostaining of tumor
samples, may identify patients who would likely benefit fromorts 12, 2060–2071, September 29, 2015 ª2015 The Authors 2069
treatment with agents that target the PI3K/mTOR and/or MAP ki-
nase signaling pathways. In addition, our study suggests that the
treatment-responsive genes we have identified could provide
intermediate biomarkers to assess short-term efficacy of combi-
nation therapy in patients, a strategy that can be readily general-
ized to other targets and therapies. Thus, our studies may inform
or modulate the design of clinical trials or help provide a mech-
anistic basis for clinical findings.
Beyond prostate cancer, our computational methodologymay
be beneficial to identify drugs that target key actionable targets
in vivo for a wide range of tumor types, oncogene and non-onco-
gene dependencies, and therapeutic agents, including both US
Food and Drug Administration-approved and experimental com-
pounds. Since many cancer types now have relevant GEM
models that are being used in many preclinical studies, it would
be advantageous to use our approach to apply these preclinical
data from GEMs to analyze treatment response in human
cancer.
EXPERIMENTAL PROCEDURES
Computational Prediction of Drug Synergy
Computational inference of drugs that inhibit FOXM1 and CENPF activity was
done using their shared target genes predicted from the mouse or human
prostate cancer interactomes and using in vivo drug perturbation data, which
were described previously (Aytes et al., 2014). Target gene reversion (i.e., inhi-
bition) was assessed using GSEA for each drug across each GEM model.
GRSs for each drug were then inferred by integrating the reversion scores
across each GEM model using a metric based on the Stouffer integration
formulation (Whitlock, 2005). Optimal drug combinations were predicted
from the single-agent in vivo drug perturbation data by determining the
SRSs for each drug using an harmonic mean (F1 statistical measure), which
maximizes the number of unique targets affected by each drug as well as
the total number of targets affected by two drugs. GSRSswere then estimated
as an average SRS weighted by the number of mouse models in which a drug
pair was estimated to be effective (i.e., to share a non-zero SRS). Details of the
computational methods used to compute GRSs and GSRSs are provided in
Supplemental Experimental Procedures, and the data are provided in Tables
S1 and S2.
Efficacy of Drug Treatment
All experiments using animals were performed according to protocols
approved by the Institutional Animal Care and Use Committee at Columbia
University Medical Center. Cell culture studies were done as described previ-
ously (Aytes et al., 2014) using human prostate cancer cell lines obtained from
ATCC and mouse cell lines derived from the GEM models used herein (Aytes
et al., 2013; unpublished date). Rapamycin and docetaxel were purchased
from LC Laboratories, and PD0325901 was provided by Pfizer. Cell culture as-
says were performed in a minimum of two independent experiments each
done in triplicate; data are presented by the mean ± SD. For in vivo studies, tu-
mor-bearing NPK mice (Aytes et al., 2013) or allografted NPK tumors were
treated with vehicle or rapamycin (10 mg/kg) and/or PD0325901 (10 mg/kg)
or docetaxel (10 mg/kg) as described previously (Kinkade et al., 2008). At
the time of sacrifice, tissues were collected for histopathological and molecu-
lar analysis as described elsewhere (Aytes et al., 2013; Kinkade et al., 2008).
GraphPad Prism software (version 5.0) was used for statistical analyses and
to generate data plots. A complete list of primers used in this study is provided
in Table S5.
Cross-Species Computational Analysis of Drug-Treatment
Signatures
Gene expression profiles based on Illumina expression arrays as in Aytes et al.
(2014) were used to generate drug-treatment signatures for the mouse tumors
or allografts, as detailed in Table S3. For comparison of mouse treatment sig-2070 Cell Reports 12, 2060–2071, September 29, 2015 ª2015 The Anatures with human signatures, the mouse genes were mapped to their corre-
sponding human orthologs. Single-sample computation of FOXM1/CENPF
activity levels or drug treatment across human patients was inferred for each
patient sample using single-sample MaRINA (ssMARINa) and GSEA, respec-
tively (Aytes et al., 2014) (see Supplemental Experimental Procedures). COX
proportional hazard model and Kaplan-Meier analysis were done using the
‘‘surv’’ and ‘‘coxph’’ functions from the survcomp package in R v2.14.0.
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